Abstract
Emphysema is a major contributor to the morbidity and mortality of chronic obstructive pulmonary disease (COPD), and there are no disease modifying therapies. Three leading pathophysiologic models are the altered protease/antiprotease balance model, the biomechanical model in which loss of one alveolar wall increases strain on adjacent wall predisposing them to failure, and the accelerated aging model. Chymotrypsin-like elastase 1 (CELA1) is a novel serine protease with a physiological role in reducing postnatal lung elastance that mechanistically links these three models. CELA1 is expressed by alveolar type 2 (AT2) cells and is found adjacent to lung elastin fibers. The KF4 antibody neutralizes CELA1 by binding to its catalytic triad. CELA1 binding to lung elastin fibers increases 4-fold with strain, and application of biaxial strain induces lung elastase activity which is blocked with the KF4 anti-CELA1 antibody. Cela1−/− mice were protected from airspace simplification in hyperoxia, elastase and cigarette-smoke induced emphysema, and age-related airspace simplification. CELA1 mRNA was correlated with human lung elastolytic activity, and anti-CELA1 KF4 antibody protected mice from hyperoxia-induced alveolar simplification and elastase emphysema. CELA1-mediated lung matrix remodeling in response to strain is an important contributor to postnatal airspace simplification. Matrix stabilization by KF4 represents a potential therapeutic approach to preventing emphysema progression.
One Sentence Summary Neutralization of chymotrypsin-like elastase 1 prevents strain-induced emphysema.
Introduction
The lung is a complex and delicate structure with a surface area of about 150 m2 through which gas exchange occurs. This surface area is accommodated by the thoracic cavity via a highly stereotyped pattern of branching airways terminating in thin alveolar sacs which are septated and perfused by an extensive capillary network. Emphysema is the term used for loss of these alveolar structures with resultant decrease in gas exchange capacity. Loss of alveoli is termed alveolar simplification or emphysema and is an element of many respiratory diseases such as bronchopulmonary dysplasia, connective tissue disorders, alpha-1 antitrypsin (AAT) deficiency, and chronic obstructive pulmonary disease (COPD). COPD is the most common cause of emphysema, accounting for about $50 billion in US health care expenditures annually. Before the COVID-19 pandemic, COPD was the 3rd leading cause of death worldwide (1). While a host of immune, epithelial, stromal, and vascular cell defects have been described, an important defect in COPD is loss of lung matrix (2). This can be observed quite strikingly in comparing lung computed tomography images of healthy and COPD subjects in which the later have loss of large areas of matrix and associated cells (3).
Among the host of extracellular matrix components in the lung, none is perhaps more important that elastin. Elastin fibers are composed of a host of elastin-associated proteins and a core of tropoelastin monomers which are hydrophobic and arranged in a repetitive overlapping pattern (4). When tension is applied to elastin fibers, potential energy is stored as these hydrophobic domains are separated giving lung its elastic properties which are key to passive exhalation. While many proteases have been shown to degrade lung elastin fibers, we have previously described a unique role for Chymotrypsin-like Elastase 1 (CELA1) in alveolar remodeling (5). CELA1 is a serine protease that has traditionally been considered a digestive enzyme but has a developmentally regulated expression pattern in AT2 cells (6). In the lung, CELA1 expression is increased with strain (7). Like other pancreatic elastases, CELA1 binds to hydrophobic domains of tropoelastin when exposed by stretch (7). The normal role for CELA1 is to reduce postnatal elastance, and Cela1−/− mice are phenotypically normal except for having higher lung elastance and smaller alveoli than wild type mice (5). CELA1 is neutralized by α1-antitrypsin (AAT) and is required for development of emphysema in a mouse model of AAT-deficient emphysema (6).
Multiple models of emphysema pathogenesis exist. The altered protease/antiprotease balance model developed after the discovery of α1-antitrypsin by Laurell and Erikson in 1964 (8) holds that unopposed protease activity leads to tissue destruction and emphysema. The accelerated aging model is based on similarities in airspace architecture between COPD and aged human lung and similar change in cellular state, oxidative stress and matrix architecture (9). The biomechanical model holds that strain is distributed over alveolar walls and associated matrix structures and that alveolar wall disruption increases strain on adjacent walls and predisposes them to failure. This manuscript details how CELA1 mechanistically unites these three models and promotes a feed-forward process of alveolar destruction.
Given the stretch-dependent nature of CELA1 in lung elastin remodeling, we hypothesized that CELA1 mediates degradation of lung elastin fibers in regions of the lung that experience localized areas of increased strain. Such a model has been predicted and validated in simulated and animal models (10–13), and is termed the biomechanical model of emphysema. In this model, loss of alveolar structure imparts additional stress on remaining structures leading to progressive airspace destruction. Here, we demonstrate that CELA1 plays an important role in emphysema progression in multiple models and at multiple stages of the life cycle, that CELA1 binds to lung elastin fibers after stretch and mediates stretch-induced lung elastase activity in healthy lung tissue. Inhibiting CELA1 with the KF4 antibody represents a potential approach to preventing emphysema progression in multiple disorders of alveolar simplification.
Results and Discussion
In the Adult Lung, CELA1 is Expressed in Surfactant Protein C-High Alveolar Type 2 Cells
We previously identified CELA1 protein in lung epithelial, immune, and mesenchymal lung cells (5) but noted that Cela1 mRNA was restricted to distal lung epithelial cells in the mouse lung and highest at E18.5 shortly before birth (7). We queried mouse and human lung cell datasets to better define CELA1-expressing cells (14, 15). The Choi, et al dataset (GSE145031) assessed lung cell expression in the murine porcine pancreatic elastase (PPE) model. As reported, alveolar type 2 (AT2) cells clustered in surfactant protein C (Sftpc)-high and Sftpc-low clusters (Figure 1A-C). Cela1 expression was almost entirely restricted to Sftpc-high cells. Sftpc-high cells represented ~60% of total AT2 cells while in PPE-treated lung they represented ~40% (Figure 1D-E). AT2 cell expressing Cela1 had higher mRNA levels of genes related to oxidative metabolism (Figure 1F). In human lung single cell analysis of control, idiopathic pulmonary fibrosis (IPF) and COPD subjects (GSE136831), CELA1 mRNA was also restricted to SFTPC-high cells; although, unlike the mouse experiment, a subset of AT2 cells with pro-inflammatory genes was observed (Figure 1G-I). Most AT2 cells in IPF and COPD lung were SFTPC-low, and almost 75% of AT2 cells in control lung were SFTPC-high (Figure 1J). Five and two percent of AT2 cells were CELA1 mRNA-positive in control and IPF or COPD lung respectively (Figure 1K). CELA1-expressing human AT2 cells also had enrichment for oxidative phosphorylation-related mRNAs (Figure 1L) demonstrating similarity between mouse and human CELA1-expressing AT2 cells. In mouse lung (Figure 1M) and human lung (Figure 1N), CELA1 mRNA and protein were present in AT2 cells. CELA1 is expressed in a similar subset of AT2 cells in mouse and human lung.
CELA1 Expression in the Injured Mouse Lung
As reported previously, Cela1 is expressed at a high level in distal lung epithelial cells at E18.5 (Supplemental Figure 1A). Cela1 expression is increased in post-pneumonectomy lung in response to strain (7). We quantified lung mRNA levels in three different mouse models of lung injury. Following PPE administration, lung Cela1 mRNA levels were variable at days 1-21 but significantly higher at 42 days compared to PBS (Supplemental Figure 1B). In the neonatal hyperoxia model, lung Cela1 mRNA levels were almost twice that of room air control (Supplemental Figure 1C). In the cigarette smoke exposure model, Cela1 mRNA levels increased with increasing duration of exposure (Supplemental Figure 1D). As each of these three models are associated with progressive airspace simplification, there is an association of increasing Cela1 expression with increasing airspace remodeling.
CELA1-binding and Stretch-Inducible Elastase Activity in Human Lung
In human lung, CELA1 was present in the extracellular matrix in association with elastin fibers (Figure 2A). CELA1 binds and cleaves non-crosslinked tropoelastin at hydrophobic domains, and we hypothesized that like other pancreatic elastases (16), CELA1 binds and cleaves tropoelastin when hydrophobic domains are exposed by strain. In mouse lung, strain increased CELA1 binding to lung elastin increased ~4-fold (7). In human lung, with increasing levels of biaxial strain the binding of fluorophore-conjugated CELA1 but not albumin increased (Figure 2B-E, Supplemental Figure 2). Biaxial stretch induces lung elastase activity in wildtype but not Cela1−/−mouse lung sections (6). In human lung sections, biaxial strain also increased lung elastase activity (Figure 2F-H) suggesting that similar strain-related remodeling programs are operative in human and mouse lung.
Human Lung CELA1 mRNA Levels Correlate with Elastolytic Activity
We quantified CELA1 mRNA and protease activity in lung homogenates from 23 non-lung organ donors and 8 COPD subjects. CELA1 mRNA levels varied logarithmically but were higher in COPD with emphysema specimens compared to control (Figure 3A). Similar patterns were observed with Matrix Metalloproteinase-8 (MMP8), MMP9, MMP12, MMP14, Proteinase-3, Cathepsin G, Neutrophil Elastase, Tissue Inhibitor of Matrix Proteinase-1 (TIMP1), TIMP2, TIMP1, and α1-Antitrypsin (SERPINA1), but not MMP2 (Supplemental Figure 3). Lung elastase, protease, and gelatinase activities were lower in COPD specimens compared to organ donor specimens (Figure 3B, Supplemental Figure 3). To investigate this apparent contradiction, we compared gene mRNA levels with protease, elastase, and gelatinase activities in each specimen. Whereas the mRNA levels of most proteases and antiproteases positively correlated with each other, CELA1 mRNA levels were not positively correlated with those of other proteases, and only CELA1 mRNA levels positively and significantly correlated with lung elastase and protease activity levels (Figure 3C).
CELA1 Genomics
The gene CELA1 was not previously identified in COPD genome wide association studies (17, 18). CELA1 is highly conserved in placental mammals (6), and CELA1 mutations in humans are rare with the most common predicted loss of function mutation having an allele frequency of 0.03% (Table 1) (19–21), and no predicted gain-of-function mutations are known (22, 23). As homozygous loss of function would be protective and occur in 1:11.7 million individuals, COPD GWAS studies would have been underpowered to identify an association of the CELA1 locus with disease.
Cela1 Deficient Mice Have Preserved Alveolar Architecture in Multiple Models of Airspace Simplification
To test whether CELA1 has a general role in airspace simplification, we tested Cela1-deficient mice in multiple models. Cela1−/− mice were protected from airspace simplification in the hyperoxia model of impaired alveolar development (Figure 4A, Supplemental Figure 4), from emphysema progression after intratracheal administration of PPE (Figure 4B, Supplemental Figure 5), from emphysema following 8 months of cigarette smoke exposure (Figure 4C, Supplemental Figure 6), and from age-related alveolar simplification (Figure 4D). The lungs of aged Cela1−/− mice had preserved elastin bundles at alveolar tips as assessed by Hart staining and brightfield microscopy, and greater total lung elastin by Western blot (Figure 4E). Although we previously reported that Cela1 mRNA and protein were increased in the mouse partial pneumonectomy model of lung regeneration (7), we found no difference in compensatory lung regrowth at 7 or 28 days (Supplemental Figure 7). Sex was not a substantial factor in these analyses (Supplemental Figures 4–7). Taken together, these data show a central role for CELA1 in alveolar destruction and no role in regeneration.
Bone Marrow Derived Immune Cells Do Not Mediate CELA1 Remodeling
To exclude the possibility that immune cells were playing a role in Cela1-mediated lung remodeling, we performed bone marrow transplantation experiments between wildtype and Cela1−/− mice. Irradiated wildtype or Cela1−/− mice were transplanted with WT or Cela1−/− bone marrow and then treated with PPE. WT recipients demonstrated an increase in mean linear intercept regardless of bone marrow genotype (Figure 5, Supplemental Figure 8), supporting AT2 cells as the relevant source of Cela1 in airspace remodeling.
Development and Validation of the KF4 Anti-CELA1 Antibody
We developed an anti-CELA1 monoclonal antibody by immunizing mice with four peptides corresponding to regions of human CELA1 with low mouse-human homology (Supplemental Table 1). Hybridomas were created, screened by ELISA and selected KF4 as our lead candidate based on inhibition of human lung elastase activity (Supplemental Figure 9). KF4 bound the N-terminal region of CELA1 in a region including the histidine of the catalytic triad (Figure 6A) (24). Immunoprecipitation of human lung homogenate with KF4 antibody identified both α1-antitrypsin complexed and native CELA1 (Figure 6B, Supplemental Figure 10). We then tested whether KF4 reduced stretch-inducible lung elastase activity. In organ donor lung sections, KF4 reduced stretch-inducible lung elastase activity to levels seen in unstretched lung (Figure 6C). In fresh mouse lung sections, KF4 reduced stretch-inducible lung elastase activity by 80% (Figure 6D-E). While the levels of strain in these ex vivo assays exceed those seen physiologically, they provide proof of principle that antibody neutralization of CELA1 inhibits strain-induced elastase activity.
KF4 Penetrates into Lung Tissue Prevents Emphysema in Multiple Mouse Models
To identify the dose of KF4 needed to reduce mouse lung elastolytic activity, we performed dosing studies in PPE-treated mice and identified an effective intraperitoneal dose of 5 mg/kg once weekly (Supplemental Figure 11A). Using fluorophore-labeled KF4, we demonstrated penetration of KF4 into mouse lung tissue in a dose-dependent manner (Figure 7A, Supplemental Figure 11B). Since Cela1−/− mice demonstrated late protection against emphysema in the PPE model, we compared emphysema in IgG and KF4-treatment beginning at the time of injury and 7 days post-injury. The KF4 antibody prevented emphysema following tracheal PPE administration with both treatment strategies (Figure 7B-C). To test the efficacy of KF4 in a different model, we utilized the neonatal mouse hyperoxia model. When KF4 was administered at 3, 7, and 10 days of life, it also improved alveolarization compared to IgG (Figure 7D). Thus, systemically administered anti-CELA1 KF4 antibody penetrated lung tissue, inhibited stretch-inducible lung elastase activity, and preserved airspace architecture in multiple models of alveolar simplification.
Discussion
We identified a unique role for CELA1 in the strain-dependent remodeling of the peripheral lung and developed a monoclonal antibody that protects against strain-induced alveolar simplification. CELA1-mediated remodeling does not dependent upon inflammation or non-resident cells, but rather, CELA1 is expressed by AT2 cells and is present in the lung extracelluar matrix but is only active with localized strain on that matrix. As such, it provides a mechanistic link between the protease-antiprotease model of emphysema and the structure-function one.
The biology of CELA1 is distinct from that of other serine and matrix metalloproteinases that have been implicated in airspace simplification. First, CELA1 is expressed by a subset of AT2 cells while other serine proteases and matrix metalloproteinases are derived from immune cells. The supposition that CELA1-mediated lung matrix remodeling represents a different program than these myeloid-derived proteases is supported by (1) our analysis of human lung showing no correlation of CELA1 mRNA levels with other proteases (except MMP12), (2) CELA1 mRNA levels but not mRNAs of other proteases being correlated with lung elastase activity, and (3) a different pattern of emphysema protection than seen in other protease-focused emphysema studies. The effects of neutrophil elastase, cathepsin G, and MMP12 showed protection at 21 days or less after injury (25–28). We found that protection of Cela1−/− mice beyond this time point. Consistent with our correlative analysis, others have found no correlation of MMP levels in bronchoalveolar lavage fluid and plasma with emphysema progression (29); although, sputum MMP12 levels are elevated in COPD (30). Alveolar macrophage depletion protected mice against elastase-induced emphysema at 7, 14, and 21 days (31), and much work has shown the interaction of MMPs and immune cells in emphysema (32). Similar to emphysema models, in the mouse hyperoxia model of BPD, MMPs, neutrophil elastase, and immune cell activation have all been shown important (33–35). Most work in age-related airspace simplification has focused on senescence and altered inflammatory responses (36). Although in a sense this work on CELA1 falls into the 50-year-old protease-antiprotease paradigm, the novelty of CELA1 lies in the cell type in which it is expressed, in its being only recently described, and the biomechanical mechanism by which it works.
CELA1 mechanistically links the protease-antiprotease and the biomechanical models of emphysema. CELA1 binds and cleaves non-crosslinked hydrophobic domains of elastin (6), and these domains are only exposed with strain. Our findings that (1) CELA1 binding to human lung elastin is enhanced by strain, (2) CELA1 inhibition reduces stretch-induced lung elastolytic activity, (3) Cela1−/− mice are protected from late but not initial airspace simplification, and (4) that post-injury treatment with KF4 is just as efficacious as pre-injury treatment all support CELA1 as being a key mediator in localized strain-mediated airspace simplification. In this model, CELA1 is expressed by AT2 cells and binds and cleaves tropoelastin with strain. This increases strain in adjacent fibers which in turn exposes additional proteolytic sites (Figure 8A-C). KF4 binds the CELA1 catalytic domain and prevents elastolysis (Figure 8D). At the microstructural level, alveolar walls can be modeled as thin, geometrically shaped membranes under low strain suspended by thin elastic fibers—the fibers in the alveolar wall. These thin fibers are in turn supported by the more rigid fibers of the alveolar duct openings which are interconnected and supported by progressively larger caliber and less compliant fibers of the small and large conducting airways and vessels and to the pleural surface. Strain is distributed over the entire network. Failure of one alveolar wall necessitates increased strain on adjacent walls which both distorts local architecture and causes an imbalance of strain on additional alveolar walls. Each wall has a threshold beyond which it too will fail imparting additional strain in its neighbors predisposing them to failure (11, 13) (Figure 8E). The biomechanical model has been validated experimentally by showing that emphysema develops in regions of mouse lung not directly exposed to PPE (37). Furthermore, the role of CELA1 in age-associated alveolar simplification is consistent with the accelerated aging model of COPD. If the same mechanisms in Figure 8 are operative in the aging lung, then CELA1 provides a mechanistic link between three models: protease/antiprotease model, biomechanical, and accelerated aging.
Our study is not without limitations. Batch-to-batch variation in PPE injury precluded comparison between experiments. The biaxial strain model applies levels of strain that would not be experienced in the human lung. While we cannot definitively state that the same process would occur under physiological strain levels, neither can we perform this experiment over the months to years over which emphysema progresses. We cannot rule out the possibility that some absent role of Cela1 on mouse lung development imparts resistance to postnatal lung injury; however, the protection conferred by anti-CELA1 KF4 antibody in multiple models makes this less likely. Lastly, we did not rigorously investigate whether CELA1 could be upstream of other alveolar simplification programs, and it is possible that our in vivo effects are not direct ones.
Conclusions
The strain-dependent elastolytic activity of CELA1 is an important factor in airspace simplification at all stages of postnatal lung life, and neutralizing CELA1 with the KF4 antibody represents a potential therapy for BPD, COPD, and other disorders of progressive airspace simplification.
Materials and Methods
Animal Use
Animal use was approved by the CCHMC Institutional Animal Use and Care Committee (2020-0054). Except for antibody production, all mice were on the C57BL/6 background, obtained from Jackson Laboratories, and equal proportions of male and female mice used in all experiments. Mice were maintained in a barrier facility with access to food and water ad libidum and 12-hour light-dark cycles.
Hyperoxia Model
Paired female mice were bred and on PND1 pups were equally distributed between the two dams to give eight mice per litter. Pups were exposed to room air or hyperoxia with switching of dams between conditions every two days. On PND14, pups were either sacrificed or moved to room air with the same dam for 14 days and then sacrificed.
Porcine Pancreatic Elastase Model
Eight- to ten-week-old mice were anesthetized with 2% isoflurane and suspended on an intubating board by the front incisors. Two units of porcine pancreatic elastase (Sigma, E1250) in 100 µL PBS was placed in the posterior oropharynx and aspirated by the breathing mouse.
Cigarette Smoke Model
Beginning at 10-12 weeks of age, mice were exposed to 4 hours of cigarette smoke five days per week for eight months using a Teague TE-10z smoking machine using smoke generated from 3R4F Kentucky Reference Cigarettes (University of Kentucky) at a concentration of 150 mg/m3 total suspended particulates.
Partial Pneumonectomy Model
Using previously described methods (38), the left lung of an anesthetized mouse was removed, mouse recovered, and tissues collected at 7 and 28 days.
Adoptive Transfer
Eight- to 10-week-old mice had ablation of bone marrow with *** for *** and rescued with tail vein injection of *** cells from the bone marrow of donor mice. Mice were allowed to recover for 4 weeks prior to additional experimentation.
Aging Model
Mice were sacrificed and collected at 72 to 75 weeks of age without any intervention.
Mouse Lung Tissue
Tissue Processing and Morphometry
After anesthetization and sacrifice by exsanguination, the mouse thorax was opened, left bronchus ligated, left lung snap frozen, trachea canulated, right inflated with at 30 cm H2O pressure in 4% PBS, fixed overnight, lung lobes separated, and paraffinized. Lung lobes were randomly oriented and embedded, sectioned, and stained using hematoxylin and eosin. Using the methods of Dunnill (39), mean linear intercepts were determined in five field per lobe. Left lungs were homogenized with extraction of RNA using RNEasy columns or processed for protein analysis.
Human Lung Tissue
Human tissue utilized under a waiver from the CCHMC IRB (2016-9641). COPD lung specimens were obtained from the NHLBI Lung Tissue Consortium, control and COPD specimens from the National Jewish Health Human Lung Tissue Consortium and from The Ohio State University Human Lung Tissue Consortium.
Enzymatic Assays
Human lung protease, gelatinase, and elastase activity was quantified using Enzcheck fluorometric assays (ThermoFisher) and elastase activity defined as rate of signal change. For comparative inhibition assays (i.e. antibody inhibition) the fractional change vs. untreated was used for comparisons.
Ex vivo Lung Stretch
Using a previously described lung stretching technique and device (6, 7, 40), the stretch-dependent binding of recombinant CELA1, albumin, and elastolytic activity of mouse and human lung sections was determined.
Proximity Ligation in situ Hybridization (PLISH) and Immunofluorescence
Using oligos in Supplemental Table 2 and previously published methods (41), CELA1 and Sftpb mRNAs were visualized with immunofluorescent co-staining using antibodies outlined in the supplement.
PCR
Taqman and Sybr Green PCR was used for mouse and human lung PCR using primers in Supplemental Tables 3&4.
anti-CELA1 Monoclonal Antibody Generation and Screening
CD-1 female mice were immunized with CELA1 peptides (Supplemental Table 1) conjugated to CRM197. Each mouse received a primary, subcutaneous immunization of 20 ug of the conjugate with 50% Titermax Gold adjuvant. The mice received subsequent immunizations of 20 ug (day 21) and 10 ug (day 35). Following the day 35 immunization serum samples were obtained and tested for reactivity with CELA1. Based on the results of the serum titration, one mouse was selected for hybridoma production. The mouse received an intravenous immunization of 2 ug of conjugate and three days later the mouse was euthanized and the spleen excised for hybridoma formation with SP2/0. Supernatants from the resulting hybridomas were tested for reactivity with CELA1 and were subsequently expanded and cloned. Antibodies from the cloned culture, derived from serum-free medium, was used in the studies reported here. Isotyping was performed using the Iso-Gold Rapid Mouse-Monoclonal Isotyping Kit (BioAssay Works Cat# KSOT03-010)
Immunoprecipitation, Western Blot, and Proteomics
Ten mg of lung homogenates from two organ donors was incubated with 100 µg KF4 antibody and antibody precipitated using Protein A/G beads, washed, and eluting using loading dye. Western blots were performed using KF4 antibody, anti-Alpha 1 antitrypsin antibody (Abcam, ab133642), and anti-tropoelastin antibody (Abcam, ab21600). Revert total protein stain was used for normalization (LICOR, 926-11011). Silver stain was performed (Santa Cruz Biotechnology, sc-2003).
Single Cell mRNA-Seq Analysis
Both mouse (14) and human (15) datasets were similarly analyzed to identify CELA1-expressing cells and perform gene set enrichment analysis of expressing vs non-expressing alveolar type 2 cells using Seurat(42) and enrichR (43) using scripts included in supplementary materials.
Statistical Methods
Using R version 4.0.2 (44), the following packages were used for statistical comparisons and graphics generation: ggpubr (45), gridExtra (46), cowplot (47), ggplotify (48), corrplot (49), and rstatix (50). For parametric data, Welch’s t-test and ANOVA with Holm-Sidac post hoc test were used, and for non-parametric data, Wilcoxon rank-sum and Kruskall-Wallis with Dunn’s post hoc test were used. For correlative analyses, Pearson’s correlation with Bonferroni correction for multiple comparisons was used. Parametric data is displayed as line and whisker plots with center line representing mean and whiskers standard deviation. Non-parametric data is displayed as box plots with center line representing median value, boxes representing 25th to 75th percentile range, and lines representing 5th to 95th percentile range. For both plot types dots represent individual data points. For all analyses p-values of less than 0.05 were considered significant.
Data Availability
After peer-review publication, the data in this manuscript will be made available upon request.
Funding
Innovation Fund, Innovation Ventures, Cincinnati Children’s Hospital (Varisco)
A1 Foundation Research Award 498262 (Varisco)
NIH/ NHBLI R01HL141229 (Varisco)
NIH/NHLBI K08HL131261 (Varisco)
NIH/NHLBI R01 HL147920 (Zemans)
NIH/NHLBI R01 HL131608 (Zemans)
Competing Interests
Cincinnati Children’s Hospital and Dr. Varisco hold patents for KF4-based therapies for the treatment of AAT-deficient and non-AAT deficient emphysema (Case 2016-0706).
Figure Legends
Tables
Acknowledgements
Reagents and Tissues: We would like to acknowledge Dr. William Janssen and the National Jewish Health Human Lung Tissue Consortium in Denver, Colorado and Dr. Meghan Ballinger and the Ohio State University Lung Tissue Repository for providing control lung tissue specimens. This study utilized biological specimens and data provided by the Lung Tissue Research Consortium (LTRC) supported by the National Heart, Lung, and Blood Institute.
Core Services: Confocal imaging support was provided by the Cincinnati Children’s Hospital (CCHMC) Confocal Imaging Core. Adoptive transfer experiments were supported by the CCHMC Irradiator Core. Proteomics Support was provided by the University of Cincinnati Proteomics Laboratory.
Footnotes
Conflict of Interest Statement: Brian Varisco and Cincinnati Children’s Hospital hold patents for the use of anti-CELA1 therapies and the KF4 antibody to prevent emphysema.
Data on the use of KF4 anti-CELA1 antibody to prevent emphysema.